Affiliation:
1. Zhangzhou affiliated hospital of Fujian medical university
2. College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University
Abstract
Abstract
Background: The first-line treatment for patients with HER2-negative advanced gastric cancer is mainly chemotherapy. Immunotherapy combined with chemotherapy has achieved encouraging results in many prospective studies, but its real-world efficacy has not yet been fully clarified. The aim of this study was to use independent sample data to explore the efficacy and safety of immunotherapy for patients with HER2-negative gastric cancer.
Methods: This study included 59 patients with HER2-negative advanced gastric cancer who received camrelizumab immunotherapy combined with chemotherapy or chemotherapy alone from April 2019 to November 2021. The endpoints were the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.
Conclusion: Compared with simple chemotherapy treatment, camrelizumab combined with chemotherapy for the first-line treatment of HER2-negative advanced gastric cancer has significant clinical benefits without increasing treatment-related complications, and it is safe and feasible.
Publisher
Research Square Platform LLC
Reference28 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA: a cancer journal for clinicians,2021;SUNG
2. A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,open-label,randomised controlled trial[J];BANG Y-J,VAN CUTSEM E,FEYEREISLOVA;The Lancet,2010
3. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J].Nature,2021;JANJIGIAN Y Y,KAWAZOE
4. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer[J].Oncology,2008,;MATSUBARA
5. of HER2 over-expressing gastric cancer patients with liver metastasis[J];DANG H-Z,YU;World J gastroenterology: WJG 2012